➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,431,154

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,431,154 protect, and when does it expire?

Patent 8,431,154 protects DALIRESP and is included in one NDA.

This patent has fifty-two patent family members in thirty-five countries.

Summary for Patent: 8,431,154
Title:Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Abstract: Dosage forms for oral administration of a PDE 4 inhibitor whose solubility is slight are described. They contain PVP as binder.
Inventor(s): Dietrich; Rango (Constance, DE), Eistetter; Klaus (Constance, DE), Ney; Hartmut (Constance, DE)
Assignee: Takeda GmbH (Constance, DE)
Application Number:13/008,842
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,431,154
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Formulation;

Drugs Protected by US Patent 8,431,154

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Astrazeneca DALIRESP roflumilast TABLET;ORAL 022522-002 Jan 23, 2018 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Astrazeneca DALIRESP roflumilast TABLET;ORAL 022522-001 Feb 28, 2011 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,431,154

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany102 07 160Feb 20, 2002
02003811Feb 20, 2002

International Family Members for US Patent 8,431,154

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 038527 ⤷  Free Forever Trial
Austria 550038 ⤷  Free Forever Trial
Australia 2003206924 ⤷  Free Forever Trial
Brazil 0307739 ⤷  Free Forever Trial
Canada 2475923 ⤷  Free Forever Trial
China 102764242 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:


Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.